scholarly journals Monitoring of Early Field Hepatic Tolerance to NNRTI-Based Regimens with Multiple Biochemical Parameters in Ivorian HIV-1-Infected Patients: A Pilot Study

2012 ◽  
Vol 03 (01) ◽  
pp. 79-89
Author(s):  
Boua Alexis Thierry Kamenan ◽  
Danho Pascal Abrogoua ◽  
Ayoman Thierry Lenoir Djadji ◽  
Dagri Monnet
Keyword(s):  
Pilot Study ◽  
Biochemical Parameters ◽  
Hiv 1

scholarly journals Male sex workers in Moscow, Russia: a pilot study of demographics, substance use patterns, and prevalence of HIV-1 and sexually transmitted infections

AIDS Care ◽  
2009 ◽  
Vol 22 (1) ◽  
pp. 112-118 ◽  
Author(s):  
Stefan Baral ◽  
Darya Kizub ◽  
Nicole Franck Masenior ◽  
Alena Peryskina ◽  
Julie Stachowiak ◽  
...  
Keyword(s):  
Substance Use ◽  
Pilot Study ◽  
Sexually Transmitted Infections ◽  
Sex Workers ◽  
Male Sex Workers ◽  
Sexually Transmitted ◽  
Use Patterns ◽  
Male Sex ◽  
Hiv 1

39. Electrophysiological diagnosis of early cns involvement in HIV-1 infection – Pilot study

2014 ◽  
Vol 125 (5) ◽  
pp. e37
Author(s):  
J. Szanyi ◽  
J. Kremláček ◽  
Z. Kubová ◽  
J. Langrová ◽  
M. Kuba ◽  
...  
Keyword(s):  
Pilot Study ◽  
Cns Involvement ◽  
Hiv 1

The diagnostic accuracy of the HIV 1/2/subtype O Tri‐line rapid test compared with ELISA: A pilot study

Oral Diseases ◽  
2020 ◽  
Vol 26 (S1) ◽  
pp. 161-164
Author(s):  
Shumani Charlotte Manenzhe ◽  
Sizakele Pride Ngwenya ◽  
Sindisiwe Londiwe Shangase
Keyword(s):  
Pilot Study ◽  
Diagnostic Accuracy ◽  
Rapid Test ◽  
Hiv 1

Once-Daily Abacavir/Lamivudine and Ritonavir-Boosted Atazanavir for the Treatment of HIV-1 Infection in Antiretroviral-Naïve Patients: A 48-Week Pilot Study

2008 ◽  
Vol 9 (3) ◽  
pp. 152-163 ◽  
Author(s):  
Richard Elion ◽  
Edwin deJesus ◽  
Michael Sension ◽  
Daniel Berger ◽  
William Towner ◽  
...  
Keyword(s):  
Pilot Study ◽  
Once Daily ◽  
Hiv 1

Changes in lipid profile and other biochemical parameters in HIV-1 infected patients

2014 ◽  
Vol 3 (7) ◽  
pp. 813 ◽  
Author(s):  
Brahmareddy Malapati ◽  
Bhavita Patel ◽  
Rita Shah ◽  
Nillawar AN ◽  
Madhu Latha ◽  
...  
Keyword(s):  
Lipid Profile ◽  
Biochemical Parameters ◽  
Hiv 1

A pilot study of raltegravir and cisplatin in head and neck squamous cell carcinoma (HNSCC).

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. TPS5602-TPS5602
Author(s):  
Julie E. Bauman ◽  
Garth T Olson ◽  
Michael Spafford ◽  
Michael Nuara ◽  
Sagus Sampath ◽  
...  
Keyword(s):  
Dna Damage ◽  
Dna Repair ◽  
Pilot Study ◽  
Replication Fork ◽  
Annexin V ◽  
Integrase Inhibitor ◽  
Primary Objective ◽  
End Joining ◽  
Cancer Society ◽  
Hiv 1

TPS5602 Background: Metnase is a recently characterized DNA repair component present in anthropoid primates. Metnase, the fusion of a SET histone methylase domain and a Transposase nuclease (Tn) domain, enhances DNA double-stranded break (DSB) repair. The Tn domain trims free DNA ends for optimal end-joining, and is required to re-start stalled replication forks. The SET domain di-methylates H3K36 at the DSB, recruiting non-homologous end-joining repair components. Cisplatin (CDDP), the central chemotherapy in HNSCC, covalently binds DNA leading to intra- and interstrand crosslinks (ICL). In addition to blocking strand transcription and segregation, the ICL stalls DNA replication fork progression leading to collapse and DSB. The role of Metnase in DNA repair, including overcoming the stalled replication fork, makes it a potential therapeutic target. We hypothesize that Metnase inhibition may be a useful adjunct to CDDP. 3D modeling of the Metnase Tn domain identified significant homology with human immunodeficiency virus 1 (HIV-1) integrase. A virtual screen of the Chem Div library identified the HIV-1 integrase inhibitor, raltegravir, as a lead compound for inhibiting the Metnase Tn domain. We designed a pilot study in HNSCC to evaluate potentiation of CDDP DNA damage by raltegravir. Methods: The primary objective of this window-of-opportunity study is to analyze biomarkers of DNA damage, fork arrest, and apoptosis in serial tumor biopsies from patients (pts) with HNSCC undergoing CDDP, with and without raltegravir. Eligible pts: 1) have HNSCC with tumor site amenable to repeat, awake biopsy; 2) are appropriate candidates for CDDP. Pts are treated with 2 doses of CDDP 30 mg/m2. One CDDP dose is administered with raltegravir 400 mg bid for 5 days, starting the day before CDDP. Pts undergo 3 research biopsies, at baseline and 48-72 hours after each CDDP. Serial biopsies will be evaluated for expression changes in γH2AX, Annexin V, pChk1, pChk2, and p53BP1 by immunohistochemistry. Numerical increase in biomarker expression in tumors exposed to CDDP-raltegravir vs. CDDP will justify development of a phase I/II study. Four of 12 pts have enrolled and completed all biopsies. Supported by a grant from the American Cancer Society.

Efficacy and tolerability of pravastatin for the treatment of HIV-1 protease inhibitor-associated hyperlipidaemia: a pilot study

AIDS ◽  
2000 ◽  
Vol 14 (11) ◽  
pp. 1660-1662 ◽  
Author(s):  
Francesco Baldini ◽  
Simona Di Giambenedetto ◽  
Antonella Cingolani ◽  
Rita Murri ◽  
Adriana Ammassari ◽  
...  
Keyword(s):  
Pilot Study ◽  
Protease Inhibitor ◽  
Hiv 1
Sign in / Sign up

Export Citation Format

Share Document